

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxml624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV 26	MARPAT enhanced with FSORT command
NEWS	4	NOV 26	CHEMSAFE now available on STN Easy
NEWS	5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC 01	ChemPort single article sales feature unavailable
NEWS	7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	14	FEB 10	COMPENDEX reloaded and enhanced
NEWS	15	FEB 11	WTEXTILES reloaded and enhanced
NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,			
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.			
NEWS HOURS STN Operating Hours Plus Help Desk Availability			
NEWS LOGIN Welcome Banner and News Items			
NEWS IPC8 For general information regarding STN implementation of IPC 8			

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

10599702

FILE 'HOME' ENTERED AT 17:18:28 ON 13 FEB 2009

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 17:18:49 ON 13 FEB 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 FEB 2009 HIGHEST RN 1105123-28-1

DICTIONARY FILE UPDATES: 12 FEB 2009 HIGHEST RN 1105123-28-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10599702.str

10599702



```
chain nodes :
10 12 13 15 16
ring nodes :
1 2 3 4 5 6 7 8 9
ring/chain nodes :
11
chain bonds :
2-11 4-10 9-15 10-12 10-13 15-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
2-11 4-10 5-7 6-9 7-8 8-9 9-15 10-12 10-13 15-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
```

G1:H,Ak

```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:CLASS 15:CLASS 16:CLASS
```


L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

10599702



G1 H, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 17:19:55 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 10 TO ITERATE

100.0% PROCESSED 10 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**



PROJECTED ITERATIONS: 11 TO 389

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=>

Uploading C:\Program Files\Stnexp\Queries\10599702.str



```

chain nodes :
10 12 13 15 16
ring nodes :
1 2 3 4 5 6 7 8 9
ring/chain nodes :
11
chain bonds :
2-11 4-10 9-15 10-12 10-13 15-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
2-11 4-10 5-7 6-9 7-8 8-9 9-15 10-12 10-13 15-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```

G1:H,Ak

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:CLASS 15:CLASS 16:CLASS

```


L3 STRUCTURE UPLOADED

=> d

L3 HAS NO ANSWERS

L3 STR

10599702



G1 H, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l3

SAMPLE SEARCH INITIATED 17:20:32 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 98 TO ITERATE

100.0% PROCESSED 98 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1367 TO 2553

PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3



=> del l1-

DELETE L1-L4? (Y)/N:y

=>

Uploading C:\Program Files\Stnexp\Queries\10599702.str

10599702



```
chain nodes :
10 12 13 15 16
ring nodes :
1 2 3 4 5 6 7 8 9
ring/chain nodes :
11
chain bonds :
2-11 4-10 9-15 10-12 10-13 15-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
2-11 4-10 5-7 6-9 7-8 8-9 9-15 10-12 10-13 15-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
```

G1:H,Ak

```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:CLASS 15:CLASS 16:CLASS
```


L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

10599702



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam

SAMPLE SEARCH INITIATED 17:21:17 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 98 TO ITERATE

100.0% PROCESSED 98 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1367 TO 2553

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1



=> del l1

L2 REFERENCES L1

DELETE L1? (Y)/N:y

=>

Uploading C:\Program Files\Stnexp\Queries\10599702.str



```

chain nodes :
10 12 13 15 16
ring nodes :
1 2 3 4 5 6 7 8 9
ring/chain nodes :
11
chain bonds :
2-11 4-10 9-15 10-12 10-13 15-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
2-11 4-10 5-7 6-9 7-8 8-9 9-15 10-12 10-13 15-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```

G1:H,Ak

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:CLASS 15:CLASS 16:CLASS

```


L3 STRUCTURE UPLOADED

=> d

L3 HAS NO ANSWERS

L3 STR

10599702



G1 H, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l3 sam

SAMPLE SEARCH INITIATED 17:22:33 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 98 TO ITERATE

100.0% PROCESSED 98 ITERATIONS

5 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1367 TO 2553


PROJECTED ANSWERS: 5 TO 234

L4 5 SEA SSS SAM L3

=> d scan

10599702

L4 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-methyl-5-[methyl(1-methyl-4-piperidinyl)amino]-7-[(4-
methyl-2-pyridinyl)amino]-
MF C24 H35 N9 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

10599702


L4 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Acetamide, N-[[1-(2-ethoxyethyl)-5-(methylamino)-7-[(4-methyl-2-
MF C19 H26 N8 O2
pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl)methyl]-



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10599702


L4 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-N-[2-(dimethylamino)ethyl]-1-(2-ethoxyethyl)-5-(
ethylamino)-
MF C21 H36 N8 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10599702

L4 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-[2-(dimethylamino)ethyl]-1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-
pyridinyl)amino]-
MF C22 H33 N9 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10599702

=> s 13 ful
FULL SEARCH INITIATED 17:23:08 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2074 TO ITERATE

100.0% PROCESSED 2074 ITERATIONS 178 ANSWERS
SEARCH TIME: 00.00.01

L5 178 SEA SSS FUL L3

=> fil capl
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 188.76 188.98

FILE 'CAPLUS' ENTERED AT 17:23:14 ON 13 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Feb 2009 VOL 150 ISS 8
FILE LAST UPDATED: 12 Feb 2009 (20090212/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:


<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 15
L6 6 L5
=> d 16 ibib hitstr abs 1-6

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:1338353 CAPLUS
 DOCUMENT NUMBER: 149:525391
 TITLE: Combinations comprising pregabalin
 INVENTOR(S): Gunn, Kevin Paul
 PATENT ASSIGNEE(S): Pfizer Limited, UK
 SOURCE: PCT Int. Appl., 45pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008132589	A1	20081106	WO 2008-IB1027	20080418
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AI, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM US 20080293746 A1 20081127 US 2008-112681 20080430 PRIORITY APPLN. INFO.: US 2007-915174P P 20070501 IT 853003-48-2 1075087-53-4 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combinations comprising pregabalin) RN 853003-48-2 CAPLUS CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N- (methylsulfonyl)- (CA INDEX NAME)				



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10599702


RN 1075087-53-4 CAPLUS

CN Hexanoic acid, 3-(aminomethyl)-5-methyl-, (3S)-, compd. with
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-
(methylsulfonyl)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxamide (1:?) (CA
INDEX NAME)

CM 1

CRN 853003-48-2

CMF C20 H28 N8 O4 S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 148553-50-8

CMF C8 H17 N O2

Absolute stereochemistry. Rotation (+).



AB The invention relates to a combination of pregabalin and
1-(2-ethoxyethyl)-5-[ethyl(methyl)amino]-N-mesyl-7-[(4-methyl-2-
pyridyl)amino]-1H-pyrazolo[4,3-d]pyrimidine-3-carboxamide, to
pharmaceutical compns. containing the combination, and to the use of the
combination in the treatment of pain. This combination fully reversed
static allodynia, indicating an increased effect if compared to pregabalin
alone.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1202023 CAPLUS

DOCUMENT NUMBER: 145:505469

TITLE: Anhydrous crystalline forms of
 N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide as PDE-5 inhibitors

INVENTOR(S): Entwistle, David Andrew; Marshall, Peter Wallace;
 Taylor, Stefan Colin John

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: PCT Int. Appl., 72pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006120552	A2	20061116	WO 2006-1B1233	20060503
WO 2006120552	A3	20070118		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006245416	A1	20061116	AU 2006-245416	20060503
CA 2608018	A1	20061116	CA 2006-2608018	20060503
EP 1881985	A2	20080130	EP 2006-744689	20060503
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
JP 2006316058	A	20061124	JP 2006-132110	20060511
NO 2007005258	A	20071115	NO 2007-5258	20071012
IN 2007DN08174	A	20071123	IN 2007-DN8174	20071023
MX 200713215	A	20071212	MX 2007-13215	20071023
US 20080194591	A1	20080814	US 2007-913091	20071030
KR 2008004593	A	20080109	KR 2007-726098	20071109
CN 101175758	A	20080507	CN 2006-80016340	20071112
PRIORITY APPLN. INFO.:			US 2005-680445P	P 20050512
			US 2005-681711P	P 20050517
			WO 2006-1B1233	W 20060503


IT 853003-48-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation and anhydrous crystalline forms of
 N-[ethoxyethyl(N-ethyl-N-methylamino)(methylpyridinylamino)pyrazolo[4,3-d]pyrimidinecarbonyl]methanesulfonamide as PDE-5 inhibitors)

RN 853003-48-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-
(methanesulfonyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
GI



I

AB The invention comprises anhydrous crystalline forms of
N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-
ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide (I),
pharmaceutical compns. comprising at least one such form, methods for the
treatment of a phosphodiesterase-5-mediated condition using at least one
such form, and methods for preparing such forms. Example compound I was
prepared

by N-alkylation of di-Me 4-nitro-1H-pyrazole-3,5-dicarboxylate with
2-ethoxyethyl bromide; the resulting di-Me
1-(2-ethoxyethyl)-4-nitro-1H-pyrazole-3,5-dicarboxylate, which underwent
hydrolysis to give the pyrazole-5-carboxylic acid derivative, which underwent
amidation to give the corresponding amide, which underwent reduction to give
Me 4-amino-5-carbamoyl-1-(2-ethoxyethyl)-1H-pyrazole-3-carboxylate, which
underwent cyclization with N,N'-carbonyldiimidazole to give Me


1-(2-ethoxyethyl)-5,7-dioxo-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate, which which underwent chlorination to give Me 5,7-dichloro-1-(2-ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate, which underwent substitution with 2-amino-4-methylpyridine; the resulting Me 5-chloro-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate underwent hydrolysis to give the corresponding carboxylic acid, which underwent amidation to give the methanesulfonamide derivative, which underwent substitution with N-methylethylamine to give compound I. Various methods to obtain different crystalline forms of I is also discussed. Compound I was evaluated

for its PDE-5 inhibitory activity.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2006:151143 CAPLUS
 DOCUMENT NUMBER: 144:219321
 TITLE: Combination of a selective noradrenaline reuptake inhibitor and a PDEV inhibitor
 INVENTOR(S): Hughes, Bernadette
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
 SOURCE: PCT Int. Appl., 72 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006016262	A1	20060216	WO 2005-IB2457	20050729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005270904	A1	20060216	AU 2005-270904	20050729
CA 2575980	A1	20060216	CA 2005-2575980	20050729
EP 1778241	A1	20070502	EP 2005-769508	20050729
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101001630	A	20070718	CN 2005-80027106	20050729
JP 2008509900	T	20080403	JP 2007-525380	20050729
BR 2005014296	A	20080617	BR 2005-14296	20050729
NO 2006006059	A	20070129	NO 2006-6059	20061229
IN 2007DN00233	A	20070803	IN 2007-DN233	20070109
MX 200700694	A	20070312	MX 2007-694	20070118
KR 2007036171	A	20070402	KR 2007-703231	20070209
KR 2008064911	A	20080709	KR 2008-715060	20080620
PRIORITY APPLN. INFO.:			GB 2004-17777	A 20040810
			US 2004-606302P	P 20040831
			EP 2004-107777	A 20040810
			WO 2005-IB2457	W 20050729
			KR 2007-703231	A3 20070209
IT 853003-47-1 853003-48-2				
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(combination of selective noradrenaline reuptake inhibitor and PDEV inhibitor in treatment of pain)				
RN 853003-47-1 CAPLUS				
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)				



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-48-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

AB The present invention relates to a combination of a selective noradrenaline reuptake inhibitor (NRI) and a phosphodiesterase type 5 (PDEV) inhibitor. Such a combination is particularly useful in the treatment of pain. For example, the combination of i.p. (S,S)-reboxetine succinate and s.c. PDEV inhibitor 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulfonyl)-2-n-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (Compound A) displayed synergy in animal models of pain. Following single administration both (S,S)-reboxetine and Compound A produced a dose dependent anti-allodynic effect in the preclin. model of chronic pain.

REFERENCE COUNT: 5


THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:1130641 CAPLUS
 DOCUMENT NUMBER: 143:387058
 TITLE: Preparation of substituted pyrazolo[4,3-d]pyrimidines as inhibitors of phosphodiesterase V
 INVENTOR(S): Bell, Andrew Simon; Brown, David Graham; Fox, David Nathan Abraham; Lu, Hwang-Fun; Marsh, Ian Roger; Morrell, Andrew Ian; Owen, Dafydd Rhys; Palmer, Michael John; Rogers, Thomas Edward; Windslow, Carol Ann
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
 SOURCE: PCT Int. Appl., 182 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097799	A1	20051020	WO 2005-IB891	20050330
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2562251	A1	20051020	CA 2005-2562251	20050330
EP 1742950	A1	20070117	EP 2005-718362	20050330
EP 1742950	B1	20081217		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
BR 2005009731	A	20070925	BR 2005-9731	20050330
JP 2007532526	T	20071115	JP 2007-506858	20050330
AT 417849	T	20090115	AT 2005-718362	20050330
MX 2006010554	A	20061208	MX 2006-10554	20060914
US 20080293697	A1	20081127	US 2006-599702	20061219
PRIORITY APPLN. INFO.:			GB 2004-7927	A 20040407
			GB 2004-7946	A 20040407
			US 2004-572024P	P 20040518
			US 2004-572049P	P 20040518
			WO 2005-IB891	W 20050330
OTHER SOURCE(S):		CASREACT 143:387058; MARPAT 143:387058		
IT 1044708-69-1 1044708-93-1 1044708-98-6				
1044709-29-6 1044709-30-9 1044709-31-0				
1044709-51-4 1044709-73-0				
RL: PRPH (Prophetic)				
(Preparation of substituted pyrazolo[4,3-d]pyrimidines as inhibitors of phosphodiesterase V)				
RN 1044708-69-1 CAPLUS				
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanamine, N-cyclopentyl-1-(2-ethoxyethyl)-5-(1-piperazinyl)-7-(4-pyrimidinylamino)-				

10599702


(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044708-93-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanamine,
N-cyclohexyl-1-(2-ethoxyethyl)-5-(1-piperazinyl)-7-(4-pyrimidinylamino)-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044708-98-6 CAPLUS

CN Cyclohexanol, 4-[[[1-(2-ethoxyethyl)-5-(1-piperazinyl)-7-(4-pyrimidinylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl]amino]methyl]-, trans-
(CA INDEX NAME)


Relative stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-29-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanamine,
N-(1,1-dimethylethyl)-1-(2-ethoxyethyl)-5-(1-piperazinyl)-7-(4-
pyrimidinylamino)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-30-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanamine,
N-ethyl-N-methyl-5-(1-piperazinyl)-7-(4-pyrimidinylamino)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-31-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanamine,
1-(2-ethoxyethyl)-5-(1-piperazinyl)-7-(4-pyrimidinylamino)-N-(2,2,2-
trifluoroethyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-51-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanamine,
N-cyclopropyl-1-(2-ethoxyethyl)-5-(1-piperazinyl)-7-(4-pyrimidinylamino)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-73-0 CAPLUS

CN Cyclohexanol, 4-[[[1-(2-ethoxyethyl)-5-(1-piperazinyl)-7-(4-pyrimidinylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)methyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 866922-33-0P 866922-37-4P 866922-39-6P

866922-41-0P 866922-43-2P 866922-45-4P

866922-48-7P 866922-49-8P 866922-51-2P

866922-52-3P 866922-53-4P 866922-56-7P

866922-59-0P 866922-62-5P 866922-66-9P

866922-70-5P 866922-73-8P 866922-91-0P

866922-93-2P 866922-95-4P 866922-97-6P

866922-98-7P 866923-00-4P 866923-01-5P

866923-02-6P 866923-03-7P 866923-04-8P

866923-05-9P 866923-06-0P 866923-07-1P


866923-08-2P 866923-25-3P 866923-29-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrazolo[4,3-d]pyrimidines as inhibitors of phosphodiesterase V)

RN 866922-33-0 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-[[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl)methyl]- (CA INDEX NAME)




10599702

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-37-4 CAPLUS


CN Methanesulfonamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-39-6 CAPLUS

CN Methanesulfonamide, N-[[1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-41-0 CAPLUS

CN Acetamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]-2-hydroxy- (CA INDEX NAME)


10599702



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-43-2 CAPLUS


CN Acetamide, N-[[1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]-2-hydroxy- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-45-4 CAPLUS

CN Acetamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (CA INDEX NAME)




10599702

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-48-7 CAPLUS


CN Acetamide, N-[[1-(2-ethoxyethyl)-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-49-8 CAPLUS

CN Acetamide, N-[[1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-51-2 CAPLUS

CN Propanamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (CA INDEX NAME)


10599702



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-52-3 CAPLUS


CN Propanamide, N-[[1-(2-ethoxyethyl)-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 866922-53-4 CAPLUS

CN Propanamide, N-[[1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-56-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,N5-dimethyl-3-[(methylamino)methyl]-N7-(4-methyl-2-
pyridinyl)- (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-59-0 CAPLUS


CN Acetamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-
pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl)methyl]-N-methyl- (CA
INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-62-5 CAPLUS

CN Acetamide, N-[[1-(2-ethoxyethyl)-5-(methylamino)-7-[(4-methyl-2-
pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl)methyl]-N-methyl- (CA
INDEX NAME)


10599702



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-66-9 CAPLUS


CN Acetamide, N-[[1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]-N-methyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-70-5 CAPLUS

CN Acetamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-(4-pyrimidinylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]-N-methyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10599702

RN 866922-73-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,N5-dimethyl-3-[(methylamino)methyl]-N7-2-pyrazinyl-,
hydrochloride (1:?) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-91-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,N5-dimethyl-3-[[(1-methylethyl)amino]methyl]-N7-(4-
methyl-2-pyridinyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-93-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)-3-
[(propylamino)methyl]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-95-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-[(ethylamino)methyl]-N5,N5-dimethyl-N7-(5-methyl-2-
pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-97-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-[(dimethylamino)methyl]-1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-(4-methyl-2-
pyridinyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-98-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-[[2-methoxyethyl]amino]methyl-N5,N5-dimethyl-N7-(4-
methyl-2-pyridinyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-00-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-[(ethylamino)methyl]-N5,N5-dimethyl-N7-(4-methyl-2-
pyridinyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-01-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-[(2-methoxyethyl)amino]-N5,N5-dimethyl-N7-4-pyrimidinyl-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-02-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-[[2-methoxyethyl)amino]methyl]-N5,N5-dimethyl-N7-4-
pyrimidinyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-03-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-[(diethylamino)methyl]-1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-4-pyrimidinyl-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-04-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,N5-dimethyl-3-[(methylamino)methyl]-N7-4-pyrimidinyl-
, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-07-1 CAPLUS

CN Ethanol, 2-[[1-(2-ethoxyethyl)-3-[(methylamino)methyl]-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-08-2 CAPLUS

CN Acetamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]-N-propyl- (CA INDEX NAME)

10599702



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 866923-25-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-[(diethylamino)methyl]-N5,N5-diethyl-N7-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 866923-24-2

CMF C22 H32 F3 N9 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 866923-29-7 CAPLUS


10599702

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanamine,
5-(1-piperazinyl)-7-(4-pyrimidinylamino)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-N-(2,2,2-trifluoroethyl)-, 2,2,2-trifluoroacetate
(1:2) (CA INDEX NAME)

CM 1

CRN 866923-28-6

CMF C20 H24 F6 N10 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


CM 2

CRN 76-05-1

CMF C2 H F3 O2



GI



AB Title compds. I [R1 = cycloalkyl, cycloalkenyl, 5-6 membered heteroarom. ring, etc.; R2 = H, alkyl; R3-4 = alk(en/yn)yl, cycloalkyl, etc.; R5 = amino, alkylenylamino, etc.; R6 = alkyl, haloalkyl, alkenyl, alkynyl, etc.] are prepared For instance II is prepared in 12 steps from di-Me 4-nitro-1H-pyrazole-3,5-dicarboxylate, 2-ethoxyethyl bromide, 2-amino-4-methylpyridine, dimethylaminoacetic acid and dimethylamine. II has an IC50 = 1.12 for phosphodiesterase 5 (PDE5). I are useful for the treatment of diabetes and hypertension.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:472160 CAPLUS
 DOCUMENT NUMBER: 143:26628
 TITLE: Preparation of pyrazolopyrimidines as cyclic guanylate
 monophosphate-specific phosphodiesterase type 5
 inhibitors
 INVENTOR(S): Bell, Andrew; Brown, David; Bull, David; Fox, David;
 Marsh, Ian; Morrell, Andrew; Palmer, Michael; Winslow,
 Carol
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
 SOURCE: PCT Int. Appl., 147 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049617	A1	20050602	WO 2004-IB3791	20041119
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2545196	A1	20050602	CA 2004-2545196	20041119
EP 1689752	A1	20060816	EP 2004-798915	20041119
EP 1689752	B1	20080227		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
BR 2004016678	A	20070213	BR 2004-16678	20041119
JP 2007512317	T	20070517	JP 2006-540655	20041119
AT 387449	T	20080315	AT 2004-798915	20041119
ES 2300849	T3	20080616	ES 2004-798915	20041119
MX 2006005824	A	20060811	MX 2006-5824	20060523
US 20070105877	A1	20070510	US 2006-580306	20060926
PRIORITY APPLN. INFO.:			GB 2003-27323	A 20031124
			WO 2004-IB3791	W 20041119

OTHER SOURCE(S): CASREACT 143:26628; MARPAT 143:26628

IT 852873-38-2P 852873-39-3P 852873-40-6P
 852873-42-8P 852873-43-9P 852873-44-0P
 852873-45-1P 852873-46-2P 852873-47-3P
 852873-48-4P 852873-49-5P 852873-50-8P
 852873-51-9P 852873-52-0P 852873-53-1P
 852873-54-2P 852873-55-3P 852873-56-4P
 852873-57-5P 852873-58-6P 852873-59-7P
 852873-60-0P 852873-61-1P 852873-62-2P
 852873-63-3P 852873-64-4P 852873-65-5P
 852873-66-6P 852873-67-7P 852873-68-8P
 852873-69-9P 852873-70-2P 852873-71-3P
 852873-72-4P 852873-73-5P 852873-74-6P


852873-75-7P 852873-76-8P 852873-77-9P
 852873-78-0P 852873-79-1P 852873-81-5P
 852873-82-6P 852873-83-7P 852873-84-8P
 852873-85-9P 852873-86-0P 852873-87-1P
 852873-88-2P 852873-89-3P 852873-90-6P
 852873-91-7P 852873-92-8P 852873-93-9P
 852873-94-0P 852873-96-2P 852873-97-3P
 852873-98-4P 852873-99-5P 852874-00-1P
 852874-01-2P 852874-02-3P 852874-03-4P
 852874-04-5P 852874-05-6P 852874-06-7P
 852874-07-8P 852874-08-9P 852874-09-0P
 852874-10-3P 852874-11-4P 852874-12-5P
 852874-13-6P 852874-14-7P 852874-15-8P
 852874-16-9P 852874-17-0P 852874-18-1P
 852874-19-2P 852874-20-5P 852874-21-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of pyrazolopyrimidines as cyclic guanylate
 monophosphate-specific phosphodiesterase type 5 inhibitors)

RN 852873-38-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
 1-(2-ethoxyethyl)-N-ethyl-5-(ethylamino)-7-(2-pyridinylamino)- (CA INDEX
 NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-39-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
 N-methyl-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-(2-
 propoxyethyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-40-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-methyl-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-42-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(methylamino)-N-[2-(methylamino)ethyl]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-43-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-[2-(dimethylamino)ethyl]-1-(2-ethoxyethyl)-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-44-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-4-piperidinyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-45-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-ethyl-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-46-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-47-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylamino)-N-[2-(methylamino)ethyl]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-48-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-[2-(dimethylamino)ethyl]-1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10599702



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-49-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-4-
piperidinyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-50-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-1-(2-ethoxyethyl)-5-[(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-51-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-(2-ethoxyethyl)-N-methyl-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-52-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-53-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-[(2-ethoxyethyl)-N-[2-(methylamino)ethyl]-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-54-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-N-[2-(dimethylamino)ethyl]-1-[(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX NAME)]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-55-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-N-4-
piperidinyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-56-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-(2-ethoxyethyl)-N-(2-methoxyethyl)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-57-5 CAPLUS

CN Glycine, N-[(5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl)carbonyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-58-6 CAPLUS

CN L-Alanine, N-[(5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.

10599702




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-59-7 CAPLUS

CN D-Alanine, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-60-0 CAPLUS


CN β-Alanine, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]carbonyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-61-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-62-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-
methyl-2-pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-63-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-methyl-5-[methyl(1-methyl-4-piperidinyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-64-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N,1-dimethyl-7-[(4-methyl-2-pyridinyl)amino]-5-(1-piperazinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-65-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N,N,1-trimethyl-5-[(3R)-3-methyl-1-piperazinyl]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-66-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-methyl-7-[(4-methyl-2-pyridinyl)amino]-5-(1-
piperazinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-67-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-methyl-5-[(3R)-3-methyl-1-piperazinyl]-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-68-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N,N-dimethyl-5-[(3R)-3-methyl-1-piperazinyl]-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.

10599702




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-69-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-70-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N,1-dimethyl-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-71-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylamino)-1-methyl-7-[(4-methyl-2-pyridinyl)amino]-N-4-piperidinyl-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-72-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-methyl-5-[(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-4-
piperidinyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-73-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-N,1-dimethyl-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-74-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-N-[2-(dimethylamino)ethyl]-1-methyl-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-75-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-methyl-7-[(4-methyl-2-pyridinyl)amino]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-76-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-methyl-7-[(4-methyl-2-pyridinyl)amino]-N-4-piperidinyl-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-77-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-1-methyl-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-78-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-methyl-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-
4-piperidinyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-79-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-methyl-N-(1-methyl-4-piperidinyl)-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-81-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-(2-ethoxyethyl)-N-(2-methoxyethyl)-7-[(5-methyl-2-pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-82-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-(2-ethoxyethyl)-N-(2-methoxyethyl)-7-(4-
pyrimidinylamino)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-83-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-ethyl-5-(ethylamino)-7-[(5-methyl-2-pyridinyl)amino]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-84-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-ethyl-5-(ethylamino)-7-(2-pyrazinylamino)- (CA INDEX
NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-85-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylamino)-N-(2-methoxyethyl)-7-[(5-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10599702



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-86-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-5-(diethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-87-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylamino)-N-methyl-7-[(4-methyl-2-pyridinyl)amino]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 852873-88-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)-N-[2-(methylamino)ethyl]- (CA INDEX NAME)




RN 852873-89-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-1-(2-ethoxyethyl)-5-(ethylamino)-N-[2-(methylamino)ethyl]- (CA INDEX NAME)




RN 852873-90-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-1-(2-ethoxyethyl)-5-(ethylmethylamino)-N-[2-
(methylamino)ethyl]- (CA INDEX NAME)



RN 852873-91-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-1-(2-ethoxyethyl)-N-ethyl-5-(1-piperazinyl)- (CA
INDEX NAME)



10599702

RN 852873-92-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-methyl-N-(1-methylethyl)-5-[methyl(1-
methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-93-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-(2-methoxyethyl)-5-(methylamino)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-94-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-N-[2-(dimethylamino)ethyl]-1-(1-methylethyl)-7-[(4-
methyl-2-pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-96-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-(2-ethoxyethyl)-N-(2-hydroxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-97-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-[2-(dimethylamino)ethyl]-5-(ethylamino)-1-(1-methylethyl)-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-98-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylamino)-N-(2-methoxyethyl)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-99-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-[(2-hydroxyethyl)methylamino]-N-methyl-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-00-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-[(2-methoxyethyl)amino]-N-methyl-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-01-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-[(2-methoxyethyl)methylamino]-N-methyl-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-02-3 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[3-[(methylamino)carbonyl]-1-(2-methylpropyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 852874-03-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 7-(cyclopentylamino)-5-(dimethylamino)-N-[2-(dimethylamino)ethyl]-1-(2-ethoxyethyl)- (CA INDEX NAME)




RN 852874-04-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-N-[2-(dimethylamino)ethyl]-1-(2-ethoxyethyl)-5-
(ethylamino)- (CA INDEX NAME)




RN 852874-05-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)-N-methyl- (CA
INDEX NAME)




RN 852874-06-7 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
 7-(cyclopentylamino)-1-(2-ethoxyethyl)-N-methyl-5-[methyl(1-methyl-4-
 piperidiny)amino]- (CA INDEX NAME)



RN 852874-07-8 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
 7-(cyclopentylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)-N-(2-
 methoxyethyl)- (CA INDEX NAME)




RN 852874-08-9 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
 7-(cyclohexylamino)-1-(2-ethoxyethyl)-N-methyl-5-[3-(methylamino)-1-
 azetidiny]- (CA INDEX NAME)



RN 852874-09-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclohexylamino)-1-(2-ethoxyethyl)-N-methyl-5-[(3R)-3-methyl-1-
piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852874-10-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclohexylamino)-1-(2-ethoxyethyl)-N-methyl-5-[methyl[(3S)-1-methyl-3-
pyrrolidinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852874-11-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-methyl-5-[methyl[(3S)-1-methyl-3-pyrrolidinyl]amino]-7-
[(4-methyl-2-pyridinyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-12-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-methyl-7-[(4-methyl-2-pyridinyl)amino]-5-[(3S)-1-
methyl-3-pyrrolidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


10599702



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 852874-13-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)-N-4-piperidinyl-
(CA INDEX NAME)



RN 852874-14-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-1-(2-ethoxyethyl)-5-(ethylamino)-N-4-piperidinyl-
(CA INDEX NAME)




RN 852874-15-8 CAPLUS

10599702


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-7-(cyclopentylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)-
(CA INDEX NAME)



RN 852874-16-9 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-7-(cyclopentylamino)-1-(2-ethoxyethyl)-5-(ethylamino)-
(CA INDEX NAME)




RN 852874-17-0 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-7-(cyclopentylamino)-1-(2-ethoxyethyl)-5-[methyl(1-
methylethyl)amino]- (CA INDEX NAME)




RN 852874-18-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-7-(cyclopentylamino)-5-(diethylamino)-1-(2-ethoxyethyl)-
(CA INDEX NAME)



RN 852874-19-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-1-(2-ethoxyethyl)-N-methyl-5-(1-piperazinyl)- (CA
INDEX NAME)



10599702


RN 852874-20-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-1-(2-ethoxyethyl)-N-(2-methoxyethyl)-5-(1-
piperazinyl)- (CA INDEX NAME)




RN 852874-21-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-methyl-1-(2-methylpropyl)-7-[(4-methyl-2-pyridinyl)amino]-5-(1-
piperazinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
GI



AB The title compds. I [R1 = (un)substituted cycloalkyl, etc.; R2 = H, alkyl; R3, R4 = (un)substituted alkyl, alkenyl, etc.; R5 = YCONR15R16; Y = alkylene, etc.; R15, R16 = H, (un)substituted alkyl, etc.; R6, which may be attached at N1 or N2, is (un)substituted alkyl, alkenyl, etc.] are prepared. Thus, 1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-5-(pyrrolidin-1-yl)-3-(pyrrolidin-1-carbonyl)-1H-pyrazolo[4,3-d]pyrimidine was prepared from Me 5-chloro-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate and pyrrolidine. Compds. of this invention in vitro showed IC50 values of 0.02 nM to 2.95 nM against cyclic guanylate monophosphate-specific phosphodiesterase type 5.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:472159 CAPLUS
 DOCUMENT NUMBER: 143:26627
 TITLE: Preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines
 with phosphodiesterase-5 (PDE5) inhibiting activity
 INVENTOR(S): Bell, Andrew Simon; Brown, David Graham; Dack, Kevin
 Neil; Fox, David Nathan Abraham; Marsh, Ian Roger;
 Morrell, Andrew Ian; Palmer, Michael John; Winslow,
 Carol Ann
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
 SOURCE: PCT Int. Appl., 282 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049616	A1	20050602	WO 2004-IB3747	20041112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004290643	A1	20050602	AU 2004-290643	20041112
AU 2004290643	B2	20080807		
CA 2546987	A1	20050602	CA 2004-2546987	20041112
EP 1689751	A1	20060816	EP 2004-798876	20041112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
CN 1882591	A	20061220	CN 2004-80034570	20041112
BR 2004016869	A	20070327	BR 2004-16869	20041112
JP 2007512314	T	20070517	JP 2006-540647	20041112
JP 4056015	B2	20080305		
SG 133614	A1	20070730	SG 2007-4860	20041112
NZ 548097	A	20081224	NZ 2004-548097	20041112
CN 101362764	A	20090211	CN 2008-10085939	20041112
CN 101362765	A	20090211	CN 2008-10085940	20041112
NL 1027568	A1	20050526	NL 2004-1027568	20041123
NL 1027568	C2	20051130		
TW 265031	B	20061101	TW 2004-93136019	20041123
US 20050245544	A1	20051103	US 2004-997191	20041124
IN 2006DN02037	A	20070803	IN 2006-DN2037	20060413
MX 2006005914	A	20060627	MX 2006-5914	20060524
KR 2007026334	A	20070308	KR 2006-710152	20060524
KR 848216	B1	20080724		
NO 2006002950	A	20060823	NO 2006-2950	20060623
KR 2008052666	A	20080611	KR 2008-709034	20080415
PRIORITY APPLN. INFO.:			GB 2003-27319	A 20031124

US 2004-535797P	P 20040112
CN 2004-80034570	A3 20041112
WO 2004-IB3747	W 20041112
KR 2006-710152	A3 20060524

OTHER SOURCE(S): MARPAT 143:26627

IT 853003-31-3P 853003-47-1P 853003-48-2P

853003-49-3P 853003-50-6P 853003-51-7P


853003-52-8P 853003-53-9P 853003-54-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of diaminopyrazolopyrimidines with phosphodiesterase-5 inhibiting activity)

RN 853003-31-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-,
2-(dimethylamino)ethyl ester (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853003-47-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-48-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853003-49-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylmethylamino)-1-[2-(3-fluoropropoxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-50-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-[2-(3-fluoropropoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-51-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-1-[2-(3-fluoropropoxy)ethyl]-7-[(4-methyl-2-
pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-52-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-1-[2-(2,2-difluoroethoxy)ethyl]-7-[(4-methyl-2-
pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-53-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-[2-(2,2-difluoroethoxy)ethyl]-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-54-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-[2-(2,2-difluoroethoxy)ethyl]-5-ethyl-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 853006-64-1P 853007-18-8P 853007-20-2P
 853007-22-4P 853007-24-6P 853007-25-7P
 853007-26-8P 853007-27-9P 853007-28-0P
 853007-29-1P 853007-30-4P 853007-31-5P
 853007-32-6P 853007-33-7P 853007-34-8P
 853007-35-9P 853007-36-0P 853007-37-1P
 853007-38-2P 853007-39-3P 853007-40-6P
 853007-41-7P 853007-42-8P 853007-43-9P
 853007-44-0P 853007-45-1P 853007-46-2P
 853007-47-3P 853007-49-5P 853007-50-8P
 853007-51-9P 853007-52-0P 853007-53-1P
 853007-54-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of diaminopyrazolopyrimidines with phosphodiesterase-5
 inhibiting activity)

RN 853006-64-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-N-
 (methylsulfonyl)- (CA INDEX NAME)




10599702

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-18-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]-, 2-(dimethylamino)ethyl ester (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853007-20-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(3-methylphenyl)amino]-N-
(methylsulfonyl)- (CA INDEX NAME)



RN 853007-22-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(6-methyl-2-pyridinyl)amino]-N-
(methylsulfonyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-24-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(methylpropylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-
(methylsulfonyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-25-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-N-
(methylsulfonyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-26-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-[(2-methoxyethyl)methylamino]-7-[(4-methyl-2-
pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-27-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[[4-(hydroxymethyl)-2-
pyridinyl]amino]-N-(methylsulfonyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-28-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-(2-ethoxyethyl)-N-(ethylsulfonyl)-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-29-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-N-(ethylsulfonyl)-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-30-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-1-(2-ethoxyethyl)-N-(ethylsulfonyl)-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-31-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(6-methyl-4-pyrimidinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-32-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-1-(2-ethoxyethyl)-7-[(6-methyl-4-pyrimidinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853007-33-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylmethylamino)-7-[(4-fluoro-3-methylphenyl)amino]-N-(methylsulfonyl)-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




RN 853007-34-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-7-[(4-fluoro-3-methylphenyl)amino]-N-(methylsulfonyl)-1-
[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




RN 853007-35-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylmethylamino)-7-[(3-methylphenyl)amino]-N-(methylsulfonyl)-1-
[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)



RN 853007-36-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylmethylamino)-1-(2-methoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-37-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-[2-(cyclobutyloxy)ethyl]-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)


10599702



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-38-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-[2-(cyclobutyloxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-39-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylmethylamino)-N-(methylsulfonyl)-1-(2-propoxyethyl)-7-(2-
pyridinylamino)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-40-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylmethylamino)-N-(ethylsulfonyl)-1-(2-propoxyethyl)-7-(2-
pyridinylamino)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-41-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-[methyl(1-methylethyl)amino]-N-(methylsulfonyl)-1-(2-propoxyethyl)-7-(2-
pyridinylamino)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-42-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(ethylsulfonyl)-5-[methyl(1-methylethyl)amino]-1-(2-propoxyethyl)-7-(2-
pyridinylamino)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-43-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-N-(methylsulfonyl)-1-(2-propoxyethyl)-7-(2-
pyridinylamino)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-44-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-N-(ethylsulfonyl)-1-(2-propoxyethyl)-7-(2-pyridinylamino)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-45-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-1-(2-propoxyethyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-46-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-1-[2-(3,3,3-trifluoropropoxy)ethyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-47-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-1-[2-(3,3,3-trifluoropropoxy)ethyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-49-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-1-[2-(3,3,3-trifluoropropoxy)ethyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-50-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-51-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-
(methylsulfonyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-52-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-1-(2-
propoxyethyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-53-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-
(methylsulfonyl)-1-(2-propoxyethyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-54-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylmethylamino)-1-(2-hydroxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-N-
(methylsulfonyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
GI



AB Title compds. [I; R1 = (substituted) cyclic group; R2 = H, alkyl; R3, R4 = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl; R5 = YC02R15, YR16; R6 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, etc.; Y = bond, CH2OCH2, alkylene, cycloalkylene; R15 = H, (substituted) alkyl; R16 = tetrazolyl, trifluoromethyltriazolyl, methylsulfonyltriazolyl, etc.; dotted lines = double bonds to form an aromatic ring], were prepared Thus, title compound (II) (preparation given) inhibited PDE-5 with IC50 = 0.075 nM.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT